The literature on CEO succession planning is nearly unanimous in its advice: Begin early, look first inside your company for exceptional talent, see that candidates gain experience in all aspects of the business, and help them develop the skills they will need in the top job. It all makes sense and sounds pretty straightforward. Nevertheless, the list of CEOs who last no more than a few years on the job continues to grow. Implicit in many, if not all, of these unceremonious departures is the absence of an effective CEO succession plan. The problem is, most boards simply don't want to talk about CEO succession: Why rock the boat when things are going well? Why risk offending the current CEO? Meanwhile, most CEOs can't imagine that anyone could adequately replace them. In this article, Kenneth W. Freeman, the retired CEO of Quest Diagnostics, discusses his own recent handoff experience (Surya N. Mohapatra became chief executive in May 2004) and offers his approach to succession planning. He says it falls squarely on the incumbent CEO to put ego aside and initiate and actively manage the process of selecting and grooming a successor. Aggressive succession planning is one of the best ways for CEOs to ensure the long-term health of the company, he says. Plus, thinking early and often about a successor will likely improve the chief executive's performance during his tenure. Freeman advocates the textbook rules for succession planning but adds to that list a few more that apply specifically to the incumbent CEO: Insist that the board become engaged in succession planning, look for a successor who is different from you, and make the successor's success your own. After all, Freeman argues, the CEO's true legacy is determined by what happens after he leaves the corner office.
Download full-text PDF |
Source |
---|
Environ Monit Assess
January 2025
School of Earth Sciences, Yunnan University, Kunming, 650500, China.
Rocky desertification (RD) is a severe phenomenon in karst areas, often referred to as "ecological cancer." However, studies on RD rarely include comparative analysis of different man-land relationship areas. This lack of analysis leads to difficulties in preventing and controlling RD in local areas with complex man-land relationships.
View Article and Find Full Text PDFJ Hazard Mater
January 2025
College of Chemical and Environmental Engineering, Hanjiang Normal University, Shiyan 442000, China. Electronic address:
Adv Healthc Mater
January 2025
Department of Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Disturbances in intracellular copper (Cu) homeostasis can trigger cuproptosis, a new form of cell death, which, when combined with photothermal therapy (PTT), offers a promising solution to the persistent challenges in colorectal cancer (CRC) treatment. In this study, a "three-level nanoparticle rocket" strategy is developed by engineering CuO, a multifunctional Cu-based nanoenzyme that is photothermal and has electron transfer properties and antioxidant efficiency. CuO effectively remodels the inflammatory environment by scavenging reactive oxygen species, thereby overcoming the traditional limitations of PTT.
View Article and Find Full Text PDFOecologia
January 2025
College of Grassland, Resources and Environment, Inner Mongolia Agricultural University, 29 Ordos Rd., Hohhot, 010011, China.
Although numerous studies have shown that grazing gives rise to community succession from the communities or even species perspective, there is a lack of discussion about how grazing drives community assembly based on plant functional traits in a long-term experiment. We find different grazing intensities lead to temporal effects on trait-mediated multidimensional community assembly processes, including community-weighted trait mean (CWM), trait filtering, and trait distribution (divergence/convergence). CWM, trait filtering, and trait distribution of different traits transformed over the 16-year grazing experiment.
View Article and Find Full Text PDFJ Neurol
January 2025
John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle-upon-Tyne, UK.
PROPEL (ATB200-03; NCT03729362) compared the efficacy and safety of cipaglucosidase alfa plus miglustat (cipa + mig), a two-component therapy for late-onset Pompe disease (LOPD), versus alglucosidase alfa plus placebo (alg + pbo). The primary endpoint was change in 6-min walk distance (6MWD) from baseline to week 52. During PROPEL, COVID-19 interrupted some planned study visits and assessment windows, leading to delayed visits, make-up assessments for patients who missed ≥ 3 successive infusions before planned assessments at weeks 38 and 52, and some advanced visits (end-of-study/early-termination visits).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!